Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen gAAP Cost of Sales ($M) ($M)
Form 10-Q / 10-K & Form 8-K GAAP to Non-GAAP Reconciliations
Latest, Q2 2026
2,811
Period ended Jun 30, 2026
Change on a year earlier
-6.6%
3,011 in Q2 2025
History
37 quarters
Since Q2 2017
Sources
32
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | GAAP Cost of Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 2,811 | -6.6% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,744 | -7.5% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 2,976 | -4.4% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 3,082 | -6.9% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 3,011 | -7.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 2,968 | -7.3% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 3,112 | 0.0% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 3,310 | +83.3% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 3,236 | +78.5% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 3,200 | +86.0% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 3,112 | +78.1% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,806 | +13.7% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 1,813 | +20.1% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 1,720 | +10.2% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,747 | +1.7% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 1,588 | -1.3% | Form 10-Q (filed 2023-10-31) ↗ |
| Q2 2022 | Jun 30, 2022 | 1,510 | -7.8% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,561 | +4.8% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,718 | +7.6% | Form 10-K (filed 2024-02-14) ↗ |
| Q3 2021 | Sep 30, 2021 | 1,609 | +3.1% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 1,637 | +10.0% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 1,490 | -1.5% | Form 10-Q (filed 2022-04-28) ↗ |
| Q4 2020 | Dec 31, 2020 | 1,597 | +27.5% | Form 10-K (filed 2023-02-09) ↗ |
| Q3 2020 | Sep 30, 2020 | 1,561 | +50.7% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,488 | +47.0% | Form 10-Q (filed 2021-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,513 | +43.4% | Form 10-Q (filed 2021-04-28) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,253 | +14.3% | Form 10-K (filed 2022-02-16) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,036 | -0.1% | Form 10-Q (filed 2020-10-29) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,012 | -1.2% | Form 10-Q (filed 2020-07-29) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,055 | +11.8% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 1,096 | +3.5% | Form 10-K (filed 2021-02-09) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,037 | +4.7% | Form 10-Q (filed 2019-10-30) ↗ |
| Q2 2018 | Jun 30, 2018 | 1,024 | 0.0% | Form 10-Q (filed 2019-07-31) ↗ |
| Q1 2018 | Mar 31, 2018 | 944 | – | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,059 | – | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2017 | Sep 30, 2017 | 990 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jun 30, 2017 | 1,024 | – | Form 10-Q (filed 2018-07-27) ↗ |
Cite this data
StockData. (2026). Amgen GAAP Cost of Sales ($M) ($M), quarterly Q2 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gaap_cogs_8k
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.